Home » Newsletters » BioWorld

BioWorld

Jan. 22, 1992

View Archived Issues

IMMULOGIC RAISES $45.5 MILLION IN OFFERING

INTERNEURON LICENSES DELIVERY TECHNOLOGY

IN OVO VACCINATION SUCCESSFUL IN TESTS

OSTEOTECH, ALZA END COLLABORATION

LIPO GETS PATENT FOR PGE1

SPLIT OVER ORPHAN DRUG AMENDMENT

LTIZ BEGINS TRIAL OF KAPOSI'S DRUG

FDA COMPLETES ONCOTRAC REVIEW

TOCOR II OFFERING RAISES $90 MILLION

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026